• $80.00
    Market Cap
  • 0.00%
    1-Year Change
  • Biotechnology
    Industry
Annual
Quarterly
12/31/2020
Income Statement
Total Operating Revenue
538,946
N/A
Cost of Revenue
196,130
N/A
Gross Profit
342,816
N/A
Sales and Marketing Expense
607,408
N/A
Research and Development Expense
-136,780
N/A
Depreciation and Amortization Expense
34,519
N/A
Total Operating Expenses
3.4M
N/A
Operating Profit
-3.1M
N/A
Interest Income
30,000
N/A
Interest Expense
-2.4M
N/A
Interest Income and Expense and Net
-2.4M
N/A
Total Nonoperating Income and Expense
-2.0M
N/A
Income before Taxes
-5.1M
N/A
Income Taxes
N/A
N/A
Extraordinary Items
N/A
N/A
Net Income
-5.1M
N/A
Net Income from Continuing Operations Applicable to Common
-5.1M
N/A
Basic EPS and Net Income
-6.79
N/A
Diluted EPS and Net Income
-6.79
N/A
Basic Weighted Average Shares
744,555
N/A
Diluted Weighted Average Shares
744,555
N/A
Balance Sheet
Cash and Cash Equivalents
19,179
N/A
Short-Term Investments
N/A
N/A
Cash and Cash Equivalents and Short-Term Investments
19,179
N/A
Total Current Assets
1.1M
N/A
Accumulated Depreciation
N/A
N/A
Property and Plant and Equipment and Net
N/A
N/A
Total Long-Term Assets
N/A
N/A
Total Assets
1.4M
N/A
Income Taxes Payable
N/A
N/A
Total Short-Term Debt
2.2M
N/A
Total Current Liabilities
10.6M
N/A
Total Long-Term Debt
1.0M
N/A
Total Long-Term Liabilities
1.1M
N/A
Total Liabilities
11.6M
N/A
Retained Earnings
-72.1M
N/A
Total Stockholders Equity
-10.2M
N/A
Total Shares Outstanding
794,183
N/A
Cash Flow
Cash from Operating Activities
-1.8M
N/A
Capital Expenditures
N/A
N/A
Cash from Investing Activities
-14,613
N/A
Dividends Paid
N/A
N/A
Cash from Financing Activities
1.8M
N/A
Financials Ratio
Gross Margin
63.61%
N/A
Operating Margin
-568.26%
N/A
Return on Assets
-293.58%
N/A
Return on Equity
58.12%
N/A
Revenue Growth
-24.19%
N/A
Current Ratio
0.11
N/A
Cash Ratio
0.002
N/A
Debt-to-Equity Ratio
-0.32
N/A
Debt-to-Assets Ratio
2.27
N/A

Earnings & Revenue History

Debt-to-Assets

Cash Flow